J Korean Med Sci.  2023 Feb;38(7):e63. 10.3346/jkms.2023.38.e63.

Relationship Between the Serum FGF21 Level and Growth in Children of Short Stature

• Lee YJ
• Jung SY
• Lee YA
• Kim J
• Lee SY
• Shin CH

• KMID: 2539539
• DOI: http://doi.org/10.3346/jkms.2023.38.e63

Abstract

Background
This study investigated the relationship between fibroblast growth factor 21 (FGF21) levels and growth in children with growth hormone deficiency (GHD) and idiopathic short stature (ISS), and the effects of the FGF21 level on response to growth hormone (GH) treatment.
Methods
We included 171 pre-pubertal children with a GHD (n = 54), ISS (n = 46), and normal height (n = 71). Fasting FGF21 levels were measured at baseline and every 6 months during GH treatment. Factors associated with growth velocity (GV) after GH therapy were investigated.
Results
The FGF21 level was higher in short children than in the controls without significant difference between the GHD and ISS groups. In the GHD group, the FGF21 level was inversely associated with the free fatty acid (FFA) level at baseline (r = −0.28, P = 0.039), however, was positively correlated with the FFA level at 12 months (r = 0.62, P = 0.016). The GV over 12 months of GH therapy was positively associated with the delta insulin-like growth factor 1 level (β = 0.003, P = 0.020). The baseline log-transformed FGF21 level was inversely associated with GV with marginal significance (β = −0.64, P = 0.070).
Conclusion
The FGF21 level was higher in children of short stature, both those with GHD and the ISS, than in children with normal growth. The pretreatment FGF21 level negatively affected the GV of children with GH-treated GHD. These results suggest the existence of a GH/FFA/FGF21 axis in children.

Keyword

Fibroblast Growth Factor 21; Growth Hormone; Growth

Figure

• 

  Fig. 1 Flowchart of the participants.SGA = small for gestational age, GHD = growth hormone deficiency, ISS = idiopathic short stature.

Reference

1. Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res. 2008; 18(2):89–110. PMID: 18182313.

2. Kliewer SA, Mangelsdorf DJ. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab. 2019; 29(2):246–253. PMID: 30726758.

3. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A. 2009; 106(26):10853–10858. PMID: 19541642.

4. Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab. 2014; 4(1):51–57. PMID: 25685689.

5. Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest. 2014; 124(9):3913–3922. PMID: 25133427.

6. Baek J, Nam HK, Rhie YJ, Lee KH. Serum FGF21 levels in obese Korean children and adolescents. J Obes Metab Syndr. 2017; 26(3):204–209. PMID: 31089518.

7. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009; 71(3):369–375. PMID: 19702724.

8. Domouzoglou EM, Vlahos AP, Cholevas VK, Papafaklis MI, Chaliasos N, Siomou E, et al. Association of fibroblast growth factor 21 with metabolic syndrome and endothelial function in children: a prospective cross-sectional study on novel biomarkers. Ann Pediatr Endocrinol Metab. 2021; 26(4):242–251. PMID: 34015901.

9. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008; 57(5):1246–1253. PMID: 18252893.

10. Chen C, Cheung BM, Tso AW, Wang Y, Law LS, Ong KL, et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care. 2011; 34(9):2113–2115. PMID: 21750278.

11. Cheng X, Zhu B, Jiang F, Fan H. Serum FGF-21 levels in type 2 diabetic patients. Endocr Res. 2011; 36(4):142–148. PMID: 21973233.

12. Semba RD, Sun K, Egan JM, Crasto C, Carlson OD, Ferrucci L. Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2012; 97(4):1375–1382. PMID: 22344195.

13. Lee Y, Lim S, Hong ES, Kim JH, Moon MK, Chun EJ, et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf). 2014; 80(1):57–64. PMID: 23278761.

14. Giannini C, Feldstein AE, Santoro N, Kim G, Kursawe R, Pierpont B, et al. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab. 2013; 98(7):2993–3000. PMID: 23626003.

15. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab. 2009; 94(6):2151–2156. PMID: 19318452.

16. Akyildiz ZI, Polat S, Yurekli BS, Kocabas GU, Tuluce K, Tuluce SY, et al. Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women. J Endocrinol Invest. 2015; 38(3):361–366. PMID: 25312836.

17. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008; 8(1):77–83. PMID: 18585098.

18. Kubicky RA, Wu S, Kharitonenkov A, De Luca F. Role of fibroblast growth factor 21 (FGF21) in undernutrition-related attenuation of growth in mice. Endocrinology. 2012; 153(5):2287–2295. PMID: 22374976.

19. Mericq V, De Luca F, Hernandez MI, Peña V, Rossel K, Garcia M, et al. Serum fibroblast growth factor 21 levels are inversely associated with growth rates in infancy. Horm Res Paediatr. 2014; 82(5):324–331. PMID: 25300595.

20. Guasti L, Silvennoinen S, Bulstrode NW, Ferretti P, Sankilampi U, Dunkel L. Elevated FGF21 leads to attenuated postnatal linear growth in preterm infants through GH resistance in chondrocytes. J Clin Endocrinol Metab. 2014; 99(11):E2198–E2206. PMID: 25137423.

21. Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J Clin Endocrinol Metab. 2010; 95(1):369–374. PMID: 19926712.

22. Kim JH, Yun S, Hwang SS, Shim JO, Chae HW, Lee YJ, et al. The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr. 2018; 61(5):135–149. PMID: 29853938.

23. Grunwald T, De Luca F. Role of fibroblast growth factor 21 (FGF21) in the regulation of statural growth. Curr Pediatr Rev. 2015; 11(2):98–105. PMID: 26133178.

24. Wu S, Levenson A, Kharitonenkov A, De Luca F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J Biol Chem. 2012; 287(31):26060–26067. PMID: 22696219.

25. Reinehr T, Woelfle J, Wunsch R, Roth CL. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab. 2012; 97(6):2143–2150. PMID: 22438225.

26. Kralisch S, Fasshauer M. Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease. Curr Opin Clin Nutr Metab Care. 2011; 14(4):354–359. PMID: 21505329.

27. Hanks LJ, Casazza K, Ashraf AP, Wallace S, Gutiérrez OM. Fibroblast growth factor-21, body composition, and insulin resistance in pre-pubertal and early pubertal males and females. Clin Endocrinol (Oxf). 2015; 82(4):550–556. PMID: 25039824.

28. Korwutthikulrangsri M, Mahachoklertwattana P, Chanprasertyothin S, Pongratanakul S, Poomthavorn P. Serum fibroblast growth factor 21 in overweight and obese Thai children and adolescents: its relation to glucose metabolism and its change after glucose loading. Clin Endocrinol (Oxf). 2015; 83(6):820–827. PMID: 25929297.

29. Chen W, Hoo RL, Konishi M, Itoh N, Lee PC, Ye HY, et al. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem. 2011; 286(40):34559–34566. PMID: 21849508.

30. Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab. 2008; 8(2):169–174. PMID: 18680716.

31. Hero M, Dunkel L, Vaaralahti K, Raivio T. Serum FGF21 in boys with idiopathic short stature: relationship to lipid profile, onset of puberty and growth. Clin Endocrinol (Oxf). 2011; 75(1):141–142. PMID: 21521270.

32. Hanks LJ, Gutiérrez OM, Bamman MM, Ashraf A, McCormick KL, Casazza K. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl Endocrinol. 2015; 2(2):77–82. PMID: 26042208.

33. Bisgaard A, Sørensen K, Johannsen TH, Helge JW, Andersson AM, Juul A. Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents. Int J Pediatr Endocrinol. 2014; 2014(1):7. PMID: 24883065.

34. Lundberg J, Höybye C, Krusenstjerna-Hafstrøm T, Bina HA, Kharitonenkov A, Angelin B, et al. Influence of growth hormone on circulating fibroblast growth factor 21 levels in humans. J Intern Med. 2013; 274(3):227–232. PMID: 23844970.